Despite the need for novel, effective therapeutics for the COVID-19 pandemic, no curative
regimen is yet available, therefore patients are forced to rely on supportive and nonspecific …

The clinical implications of COVID-19 have changed since SARS-CoV-2 first emerged in
humans. The current high levels of population immunity, due to prior infection and/or …

Background Nirmatrelvir is a protease inhibitor with in-vitro activity against SARS-CoV-2,
and ritonavir-boosted nirmatrelvir can reduce the risk of progression to severe COVID-19 …

Changes to the national COVID-19 monitoring strategy and COVID Data Tracker capitalize
on marked improvements in multiple surveillance systems. Weekly COVID-19 hospital …

Description: The American College of Physicians and American Academy of Family
Physicians developed this guideline to present the available evidence on current …

Drug treatment of COVID-19 infection : Current Opinion in Pulmonary Medicine Drug treatment
of COVID-19 infection : Current Opinion in Pulmonary Medicine Log in or Register Subscribe to …

Introduction Elderly patients are the most affected and vulnerable to COVID-19 and effective
therapeutic interventions are urgently required. We clarified the safety and efficacy of …

Oral nirmatrelvir/ritonavir is approved as treatment for acute COVID‐19, but the effect of
treatment during acute infection on risk of Long COVID is unknown. We hypothesized that …

Our study is aimed to access the efficacy and safety outcomes for coronavirus disease 2019
(COVID‐19) patients treated with Paxlovid. According to inclusion and exclusion criteria …

Several randomized controlled trials and real‐world cohort studies have demonstrated the
efficacies of nirmatrelvir plus ritonavir (NMV‐r) and molnupiravir (MOV) in at‐risk patients …